Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 15;61 Suppl 5(Suppl 5):S531-9.
doi: 10.1093/cid/civ601.

Influence of Age on Antibody Response and Persistence Following Immunization With MenAfriVac

Yuxiao Tang  1 , Brian D Plikaytis  2 , Marie-Pierre Preziosi  3 , Ray Borrow  4
Affiliations

Influence of Age on Antibody Response and Persistence Following Immunization With MenAfriVac

Yuxiao Tang et al. Clin Infect Dis. .

Abstract

Background: A meningococcal group A conjugate vaccine, PsA-TT (MenAfriVac), developed through the Meningitis Vaccine Project and manufactured by the Serum Institute of India, Ltd, was tested in multiple clinical trials conducted mainly in Africa. The impact of age at which subjects were vaccinated on immune response and persistence postimmunization with PsA-TT was the main focus of the current analysis.

Methods: Subjects who were vaccinated with a single dose of 10 µg of PsA-TT at 12-23 months or 22-33 months of age in study A conducted in Mali and The Gambia; at 2-10 years, 11-17 years, or 18-29 years of age in study B conducted in Mali, The Gambia, and Senegal; and at 14-18 weeks, 9-12 months, or 12-18 months of age in study C conducted in Ghana are included in the current analysis. Immunogenicity was measured by group A serum bactericidal antibody (SBA) titer with baby rabbit complement.

Results: Significant differences in SBA titers were found among the age groups in studies B and C both 28 days and 1 year postimmunization. A significant difference in SBA titers between age groups 12-23 months and 22-33 months was only observed 1 year postimmunization in study A. Antibody titers remained at similar levels from 1 to 2 years postimmunization for subjects vaccinated at 12-23 months in study A and at 9-12 months or 12-18 months of age in study C.

Conclusions: Subjects immunized at different ages had different postimmunization immune responses as measured by SBA titers. Toddlers tended to have higher immune responses than infants. This pattern persisted at least 1 year postimmunization.

Clinical trials registration: ISRCTN78147026 (study A), ISRCTN87739946 (study B), and ISRCTN82484612 (study C).

Keywords: MenAfriVac; age; meningococcal group A conjugate vaccine; serum bactericidal antibody.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Reverse cumulative distribution curves for serum bactericidal antibody (SBA) titers by follow-up time and age of subjects at immunization. A, Prior to immunization. B, 28 days after immunization.
None
C, One year after immunization. D, Two years after immunization.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Molesworth AM, Thomson MC, Connor SJ et al. . Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa. Trans R Soc Trop Med Hyg 2002; 96:242–9. - PubMed
    1. LaForce FM, Konde K, Viviani S, Préziosi MP. The Meningitis Vaccine Project. Vaccine 2007; 25(suppl 1):A97–100. - PubMed
    1. World Health Organization. Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec 2011; 86:521–40. - PubMed
    1. Sow SO, Okoko BJ, Diallo A et al. . Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011; 364:2293–304. - PubMed
    1. Maslanka SE, Gheesling LL, Libutti DE et al. . Standardization and a multilaboratory comparison of Neisseria meningitidis group A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 1997; 4:156–67. - PMC - PubMed